Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PR3mutB-CATCR-T cells
- Development stage
- Preclinical
- Lead developer
- Winnow Therapeutics
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
PR3mutB-CATCR-T cells is an investigational chimeric autoantigen T cell receptor (CATCR)-T cell therapy being developed for the treatment of proteinase 3 (PR3)-specific antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) [0928]. CATCR-T cells express a disease-relevant autoantigen fused to a modified T cell receptor, enabling selective targeting of autoreactive B cells through their B cell receptors [0928]. To avoid off-target binding to physiologic ligands such as NB1 (CD177) on normal cells, PR3mutB-CATCR-T cells utilize a structure-guided engineered PR3 variant (PR3mutB) that eliminates off-target binding while maintaining potent cytotoxicity against pathogenic PR3-ANCA+ B cells [0928].
- Other names
- PR3mutB-CATCRco-T cellsPR-3mutB-CATCRco-T cellsPR 3mutB-CATCRco-T cells
Beyond the preview
Go deeper on PR3mutB-CATCR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PR3mutB-CATCR-T cells.